Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR001884)
Formula
SVG example
O-Demethylation
Reactant Oxycodone hydrochloride Product Oxymorphone
Reactant Info Product Info
Metabolic Enzyme Cytochrome P450 2D6 (CYP2D6) DME Info
Metabolic Type Oxidation - O-Demethylation
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR001883 Oxycodone hydrochloride 6beta-Oxycodol Reduction - Reduction Oxycodone hydrochloride [1]
MR001882 Oxycodone hydrochloride Alpha-Oxycodol Reduction - Reduction Oxycodone hydrochloride [1]
MR001881 Oxycodone hydrochloride Noroxycodone Oxidation - N-Demethylation Oxycodone hydrochloride [1], [2], [3]
Other MR(s) Related to The Product of This MR
Other MR(s) That Produce The Product of This MR
MR ID Reactant Product MR Type Related Drug REF
MR010792 Naloxone Naloxone Metabolite M5 Unclear - Unclear Naloxone [4]
MR013820 Oxycodone Oxymorphone Unclear - Unclear Oxycodone [5]
MR001905 Oxymorphone Oxymorphone Oxidation - O-Demethylation Oxymorphone [6]
MR010784 Zanubrutinib Zanubrutinib Metabolite M5 Unclear - Unclear zanubrutinib [7]
References
1 Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54.
2 Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer. Clin Pharmacokinet. 2023 May 10. doi: 10.1007/s40262-023-01255-1.
3 Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests. Pharmacogenomics J. 2022 Feb;22(1):25-32. doi: 10.1038/s41397-021-00253-5.
4 Optimization of Mass Spectrometry Imaging for Drug Metabolism and Distribution Studies in the Zebrafish Larvae Model: A Case Study with the Opioid Antagonist Naloxone
5 Metabolism and Disposition of Prescription Opioids: A Review
6 Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010 Jul;70(1):78-87.
7 In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.